Navigation Links
IntraOp Medical wins Patent Defense Suit Protecting Their Intellectual Property
Date:2/1/2012

SUNNYVALE, Calif., Feb. 1, 2012 /PRNewswire/ -- IntraOp Medical Corporation  (OTC: IOPD) is pleased to  announce that the German Supreme Court dismissed the patent nullification case that IntraOp Medical had appealed, and have upheld IntraOp's Mobetron patent for a mobile IOERT linear accelerator with "straight through" accelerator guide design without a bending magnet with a slight clarification.

IntraOp Medical's European Patent EP 0 700 578 describes for the Federal Republic of Germany an electron linear accelerator treatment device, which is suitable for Intra-Operative Electron Beam Radiation Therapy (IOERT).  This patent has been maintained with a slight revision to better clarify the device. The German text of the European Patent EP 0 700 578 may be obtained from the German Patent and Trademark Office Link.

"It is good to have this ruling validate the inventiveness of the Mobetron, which has provided the clinical community a totally new way to deliver IOERT.  The Mobetron mobile IOERT technology has already enabled important clinical studies in early stage breast cancer, and clinical trials for pancreatic cancer and rectal cancer are being developed. These studies would not have been practical or even possible to implement without the Mobetron mobile IOERT development," said Don Goer, Chief Scientist and founder of IntraOp.  John Powers, IntraOp CEO further said "we will continue to aggressively defend our patents.  This decision clearly helped reinforce the strength of our IP."

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications with excellent results. for example the IOERT Breast Boost has shown unparallel results in clinical studies for treating breast cancer with less than 1% recurrence in 10 years. The Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Contact: IntraOp Medical Corporation
John Powers, 408-636-1020 ext. 128   email: jpowers@intraopmedical.com

 


'/>"/>
SOURCE IntraOp Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diablo Valley Oncology Performs Breast Intraoperative Radiation Procedure - First in the East Bay
2. FDA and Industry Reach Agreement in Principle on Medical Device User Fees
3. The VWR Foundation Auction Raises $75,000 for Childrens National Medical Center
4. Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol
5. Concord Medical Services Holdings Limited Engages Solebury Communications Group LLC to Establish a Strategic Investor Relations Program
6. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
7. What Recession? How Biomedical Device Companies Thrived in a Bad Economy
8. Medical Alarm Concepts and Harrington Media Announce Final Schedule for MediPendant™ Nationwide Television Test Launch
9. Leesburg Regional Medical Center Physicians Perform Regions First Aortic Valve Replacement via Catheter
10. Varian Medical Systems Uses SAP to Support Sustainability and Compliance With REACH and RoHS
11. PPD and VirtualScopics Expand Strategic Alliance for Medical Imaging Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... , ... Shark Finds and Kevin Harrington, along with the Product ... with Belly Bands. , Having a dog is great—except when it wets every couch, ... nothing works, get Belly Bands, the easiest way to stop dogs from wetting ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The Muscular Dystrophy Association and Sailormen Inc., ... 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise critical ... diseases that severely limit strength and mobility. , Now through March 20, ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an ... Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the ... successfully completed his first three-year term as chief and began a second three-year term ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends ... water may be safer than regular municipal or well water. The recent experience with ... Sharon Kleyne, could go a long way toward increasing public acceptance of recycled waste ...
Breaking Medicine News(10 mins):